Leading Pharma Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: Leading Pharma Pharmaceutical Import Records from India — 2 Products, $5.7M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Leading Pharma — Pharmaceutical Importer Profile (2026) | 2 Products, $5.7M Trade | TransData Nexus

Leading Pharma

Pharmaceutical Importer · United States · Antibiotics Focus · $5.7M Total Trade · DGFT Verified

Leading Pharma is a pharmaceutical importer based in United States with a total trade value of $5.7M across 2 products in 2 therapeutic categories. Based on 113 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Leading Pharma sources from 5 verified Indian suppliers, with Fdc Limited accounting for 39.7% of imports.

Leading Pharma — Import Portfolio & Supplier Network

Leading Pharma import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Leading Pharma?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Fdc Limited	$4.4M	161	39.7%
Medley Pharmaceuticals Limited	$4.2M	121	37.8%
Graviti Pharmaceuticals Private Limited

What Formulations Does Leading Pharma Import?

Formulation	Value	Ships
Ciprofloxacin ophthalmic solution USP 0.	$1.1M	23
Dorzo (drz) + timo os USP 10ML	$619.4K	17
Ciprofloxacin ophthalmic solution USP 0.3% 5	$393.9K	9
Fenofibric acid delayed release	$302.8K	25
Ciprofloxacin ophthalmic solution USP 0.3% 5ML (ciprofloxacin ophthalmic solution USP 0.3% w/v)	$300.0K	6
Nystatin oral suspension 100mu/ML, USP (473ML)(other details as per invoice)	$250.0K	5
Dorzo (drz)+timo os USP 10ML	$245.8K	5
Nystatin oral suspension 100mu/ML, USP (60ML)(other details as per invoice)	$214.5K	5
Nystatin oral suspension 100mu ML USP 473ML rest as per	$200.0K	4
Ciprofloxacin ophthalmic solution USP 0 3 2 5ML ciprofloxacin ophthalmic solution USP 0 3 w	$172.2K	4
Dorzo drz timo os USP 10ML dorzolamide hydrochloride and timolol maleate ophthalmic solution	$154.5K	4
Varenicline 0.5 MG+1MG tablets 53t 11 TAB of 0.5MG and 42 TAB of 1MG qty.0.5 MG = 119592 TAB & 1 MG = 456624 TAB	$150.0K	3
Nystatin oral suspension 100mu/ML, USP (473ML) (rest as per invoice)	$150.0K	3
Dorzolamide (drz) os USP 10ML	$140.7K	3
Dorzolamide (drz) os USP 10ML(lut (arn)	$140.7K	3

Leading Pharma imports 228 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Ciprofloxacin	Antibiotics	$3.5M	70	1.2%	13
2	Ofloxacin	Advanced Antibiotics	$2.1M	43	0.7%	16

Leading Pharma imports 2 pharmaceutical products across 2 categories into United States totaling $5.7M.

Leading Pharma — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Leading Pharma is a United States-based pharmaceutical importer specializing in the procurement of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Headquartered in Fairfield, New Jersey, the company plays a pivotal role in the U.S. pharmaceutical distribution network by sourcing a diverse array of generic medications from international suppliers, particularly from India. This strategic sourcing enables Leading Pharma to offer cost-effective therapeutic options to the U.S. market, thereby enhancing access to essential medicines.

The company's import portfolio is notably concentrated, with a total import value of $5.7 million USD across 113 shipments from India between 2022 and 2026. This concentration underscores Leading Pharma's strategic focus on specific therapeutic areas, particularly antibiotics, which constitute 61.9% of their imports, and advanced antibiotics, accounting for 38.1%. Such a focused approach allows the company to leverage economies of scale and establish strong partnerships with key suppliers, ensuring a steady supply of high-demand pharmaceutical products.

2Distribution Network

Leading Pharma's distribution network is designed to efficiently deliver pharmaceutical products across the United States. While specific warehouse locations are not publicly disclosed, the company's operations are centralized in Fairfield, New Jersey, positioning it strategically to serve major metropolitan areas in the Northeast and beyond. The logistics capabilities of Leading Pharma are robust, enabling timely and reliable delivery of pharmaceutical products to various stakeholders, including wholesalers, healthcare providers, and pharmacies. This logistical efficiency is crucial in maintaining the integrity of the pharmaceutical supply chain and ensuring that medications reach end-users without delay.

3Industry Role

In the U.S. pharmaceutical supply chain, Leading Pharma functions primarily as a pharmaceutical importer and distributor. By sourcing finished pharmaceutical formulations from international manufacturers, especially those in India, the company acts as an intermediary between foreign producers and the U.S. market. This role is vital in introducing a diverse range of generic medications to the U.S., thereby enhancing competition and potentially reducing healthcare costs. Leading Pharma's operations contribute to the overall efficiency and resilience of the pharmaceutical supply chain, ensuring that a wide array of therapeutic options is available to meet the needs of the U.S. population.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Leading Pharma

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Leading Pharma's sourcing strategy exhibits a high degree of concentration, with the top five products—Ciprofloxacin and Ofloxacin—accounting for 100% of their imports from India. This singular focus on two antibiotic formulations suggests a strategic decision to specialize in high-demand, cost-effective medications within the antibiotic category. While such concentration can lead to favorable pricing and strong supplier relationships, it also introduces potential risks. For instance, any disruptions in the supply chain for these specific products, such as manufacturing issues or regulatory challenges, could significantly impact Leading Pharma's ability to meet market demand. Therefore, the company must maintain vigilant oversight of its supply chain and be prepared to implement contingency plans to mitigate potential disruptions.

The shipment data indicates a stable relationship with key suppliers, including FDC Limited and Medley Pharmaceuticals Limited, which together account for a substantial portion of the import value. This stability is essential for maintaining a consistent supply of the specified antibiotic formulations. However, the lack of diversification in the product portfolio means that any changes in the dynamics of these supplier relationships could have a disproportionate effect on Leading Pharma's operations. To mitigate such risks, the company may consider exploring additional suppliers or expanding its product range to enhance resilience and adaptability in the face of potential supply chain challenges.

2Supply Chain Resilience

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation of pharmaceutical products. The FDA ensures that all imported drugs meet the standards for quality, safety, and effectiveness as outlined in the Federal Food, Drug, and Cosmetic Act (FD&C Act). This comprehensive framework governs the importation process, including the registration and listing of foreign drug establishments, labeling requirements, and compliance with good manufacturing practices (GMP). For Indian pharmaceutical exporters, understanding and adhering to FDA regulations is crucial for successful market entry and sustained operations within the U.S. market.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products entering the U.S. are stringent. Foreign drug establishments must register with the FDA and list all their drug products intended for importation. Additionally, these establishments must comply with FDA's good manufacturing practices (GMP) to ensure product quality and safety. The FDA recognizes GMP certifications from reputable international bodies, including the European Union (EU) GMP, World Health Organization (WHO) GMP, and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). For Indian exporters, obtaining these certifications and ensuring compliance with FDA regulations are essential steps in the importation process. Furthermore, wholesale distribution authorization is required for entities involved in the distribution of pharmaceutical products within the U.S. market.

Leading Pharma — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Leading Pharma's product strategy focuses on the importation of specific antibiotic formulations, notably Ciprofloxacin and Ofloxacin. This focus aligns with the high demand for these antibiotics in the U.S. market, driven by their effectiveness in treating a range of bacterial infections. The company's strategic emphasis on these products allows it to establish strong supplier relationships and achieve economies of scale, thereby offering competitive pricing to U.S. consumers. By concentrating on these therapeutic areas, Leading Pharma can effectively meet market needs and position itself as a key player in the antibiotic segment of the U.S. pharmaceutical market.

2Sourcing Profile

Leading Pharma's sourcing strategy is centered on generic drug formulations, particularly antibiotics, sourced from India. This approach leverages India's status as a major global supplier of affordable and high-quality generic medications. By focusing on specific formulations, Leading Pharma can ensure product consistency and quality, which are critical for maintaining trust with U.S. healthcare providers and patients. India's well-established pharmaceutical manufacturing sector, with its adherence to international GMP standards, makes it a reliable partner for Leading Pharma's procurement needs.

3Market Positioning

Seller's Guide — How to Become a Supplier to Leading Pharma

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to engage with Leading Pharma, particularly those offering high-quality antibiotic formulations that meet FDA standards. The company's focused product strategy and established supplier relationships indicate a preference for consistent and reliable sources. Indian exporters can capitalize on this by ensuring compliance with FDA regulations, obtaining necessary certifications, and demonstrating the quality and efficacy

TransData Nexus Research · Industry procurement practicesMar 2026

Frequently Asked Questions — Leading Pharma

What products does Leading Pharma import from India?

Leading Pharma imports 2 pharmaceutical products across 2 categories. Top imports: Ciprofloxacin ($3.5M), Ofloxacin ($2.1M).

Who supplies pharmaceuticals to Leading Pharma from India?

Leading Pharma sources from 5 verified Indian suppliers. The primary supplier is Fdc Limited (39.7% of imports, $4.4M).

What is Leading Pharma's total pharmaceutical import value?

Leading Pharma's total pharmaceutical import value from India is $5.7M, based on 113 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Leading Pharma focus on?

Leading Pharma imports across 2 categories. The largest: Antibiotics (61.9%), Advanced Antibiotics (38.1%).

Get Full Leading Pharma Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.